Acadia Pharmaceuticals | ACAD - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
ALKERMES USD 187.2M 15.43M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Cara Therapeutics USD 2.19M 2.45M 2025-09
Corcept Therapeutics USD 114.74M 7.77M 2025-12
Cytokinetics USD 91.72M 67.02M 2025-12
Eisai JPY 111.72B 7.86B 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Incyte USD 390.41M 61.33M 2025-12
J&J USD 6.75B 831M 2025-12
Moderna USD 308M 40M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Pfizer USD 4.08B 894M 2025-12
Prothena USD 7.65M 5.59M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12